여성 불임 진단 시장 규모, 점유율 및 동향 분석 보고서 : 검사별, 지역별, 부문별 예측(2024-2030년)

Female Infertility Diagnosis Market Size, Share & Trends Analysis Report By Test (Ovarian Reserve Testing, Hormone Testing, Hysterosalpingography, Other Tests), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,656,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,111,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,021,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

여성 불임 진단 시장 동향

세계 여성 불임 진단 시장 규모는 2023년 44억 5,000만 달러로 추정되며, 2024년부터 2030년까지 연평균 8.6%의 성장률을 보일 것으로 예상됩니다. 2023년 6월에 발표된 세계보건기구(WHO) 보고서에 따르면, 가임기 여성의 약 8-13%가 다낭성난소증후군(PCOS)을 앓고 있으며, 전 세계 여성의 최대 70%가 다낭성난소증후군을 앓고 있는 것으로 나타났습니다. 전 세계적으로 최대 70%가 진단을 받지 못하고 있습니다.

예를 들어, 2022년 6월 Journal of Korean Medical Science지에 게재된 연구에 따르면, 한국은 지난 30년간 OECD 회원국 중 출산율이 가장 많이 감소하고 있습니다. 한국 정부는 이러한 추세에 따라 건강한 임신과 출산을 장려하는 것의 중요성을 인식하고, 2021년부터 시작된 '제4차 저출산-고령사회기본계획' 등의 노력을 통해 저출산 대책과 고령 임신을 지원하기 위한 정책을 도입하고 있습니다. 이에 따라 저출산은 불임 진단 및 보조생식술에 대한 수요를 증가시켜 시장 성장의 확대로 이어질 것으로 예상됩니다.

생활습관은 남녀 모두 불임에 큰 영향을 미칩니다. 흡연, 과도한 음주, 불규칙한 식습관, 좌식생활 등의 요인은 생식기능에 부정적인 영향을 미칠 수 있습니다. 또한, 이러한 생활습관은 호르몬 불균형, 산화 스트레스, 염증, 생식기능 저하 등 다양한 메커니즘을 통해 생식능력에 영향을 미칠 수 있으며, WHO에 따르면 불임의 유병률은 중저소득 국가에서 16.5%, 고소득 국가에서는 17.8%에 달할 전망입니다.

여성 불임 진단 세계 시장 세분화 보고서

이 보고서는 2018년부터 2030년까지 국가별 수익 성장을 예측하고 각 하위 부문의 최신 산업 동향과 수익 기회에 대한 분석을 제공합니다. 이 연구에서 Grand View Research는 여성 불임 진단 시장 보고서를 검사 및 지역을 기준으로 다음과 같이 세분화했습니다.

• 검사 전망(매출액, 2018-2030년)
• 난소 예비능 검사
• 자궁 난관 조영 검사
• 호르몬 검사
• 기타 검사
• 지역 전망(수입, 2018-2030년)
• 북미

미국

캐나다

멕시코

• 유럽

영국

독일

프랑스

이탈리아

스페인

덴마크

스웨덴

노르웨이

• 아시아태평양

일본

중국

인도

호주

한국

태국

• 라틴아메리카

브라질

아르헨티나

• 중동 및 아프리카

남아프리카공화국

사우디아라비아

아랍에미리트(UAE)

쿠웨이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 여성 불임 진단 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 여성 불임 진단 시장 분석 툴
  • Porter의 Five Forces 분석
  • PESTEL 분석

제4장 여성 불임 진단 시장 : 검사 추정·동향 분석

• 부문 대시보드
• 여성 불임 진단 시장 : 테스트 변동 분석
• 여성 불임 진단 시장 : 검사별 전망
• 난소 예비능 검사
• 자궁 난관 조영 검사
• 호르몬 검사
• 기타 테스트

제5장 여성 불임 진단 시장 : 지역 추정·동향 분석

• 지역 대시보드
• 지역별 여성 불임 진단 시장 : 중요 포인트
• 북미
  • 북미의 여성 불임 진단 시장 추산·예측, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
  • 유럽
  • 유럽 여성 불임증 진단 시장 추산·예측, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양의 여성 불임 진단 시장 추산·예측, 2018-2030년
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 라틴아메리카의 여성 불임 진단 시장 추산·예측, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카의 여성 불임 진단 시장 추산·예측, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제6장 경쟁 구도

• 시장 진출기업 분류
• 기업 시장 현황 분석
• 주요 기업 개요
  • PFCLA
  • Mayo Foundation for Medical Education and Research(MFMER)
  • Cleveland Clinic
  • Apricity Fertility UK Limited
  • King's Fertility Limited
  • Dallas IVF
  • Midwest Fertility Specialists
  • Europe IVF
  • Care Fertility
  • Aspire Fertility

LSH

영문 목차

영문목차

Female Infertility Diagnosis Market Trends

The global female infertility diagnosis market size was estimated at USD 4.45 billion in 2023 and is projected to grow at a CAGR of 8.6% from 2024 to 2030. The market's growth is driven by the growing changes in lifestyle, which contribute to the rise in infertility and the prevalence of conditions such as polycystic ovary syndrome (PCOS). According to a World Health Organization (WHO) report published in June 2023, PCOS affects approximately 8-13% of women of reproductive age, with up to 70% of those affected going undiagnosed globally.

Additionally, a constant increase in the incidence of infertility in both sexes is projected to drive the market.For instance, according to a study published in Journal of Korean Medical Science, in June 2022, South Korea has experienced the most significant decline in fertility rates among all OECD countries in the last three decades. The Korean government has acknowledged the importance of promoting healthy pregnancies and childbirth considering this trend and has introduced policies aimed at addressing the low fertility rate and supporting advanced maternal age pregnancies through initiatives such as 'The Fourth Basic Plan on Low Fertility and Aging Society' launched in 2021. Consequently, the low fertility rate is expected to drive up the demand for infertility diagnosis and assisted reproductive technologies, leading to an expansion in the market growth.

The lifestyle habits play a significant role in influencing fertility in both men and women. Factors such as smoking, excessive alcohol consumption, poor diet, and sedentary habits can have detrimental effects on reproductive health. In addition, these lifestyle habits can impact fertility through various mechanisms, including hormonal imbalances, oxidative stress, inflammation, and impaired reproductive function. According to WHO, prevalence of infertility is 16.5% in low & middle income countries and 17.8% in high income countries.

Global Female Infertility Diagnosis Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the female infertility diagnosis market report based on test and region:

• Test Outlook (Revenue, USD Million, 2018 - 2030)
• Ovarian Reserve Testing
• Hysterosalpingography
• Hormone testing
• Other Tests
• Region Outlook (Revenue, USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

• Latin America

Brazil

Argentina

• Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Tests
    • 1.1.1.2. Regional scope
  • 1.1.2. Estimates and forecasts timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.1.3. Purchased database
  • 1.1.4. GVR's internal database
  • 1.1.5. Secondary sources
  • 1.1.6. Primary research
  • 1.1.7. Details of primary research
• 1.4. Information or Data Analysis
  • 1.1.8. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.1.9. Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Female Infertility Diagnosis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Female Infertility Diagnosis Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis

Chapter 4. Female Infertility Diagnosis Market: Tests Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Female Infertility Diagnosis Market: Tests Movement Analysis
• 4.3. Female Infertility Diagnosis Market by Tests Outlook (USD Million)
• 4.4. Ovarian Reserve Testing
  • 4.4.1. Ovarian Reserve Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Hysterosalpingography
  • 4.5.1. Hysterosalpingography Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Hormone Testing
  • 4.6.1. Hormone Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Other Tests
  • 4.7.1. Other Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Female Infertility Diagnosis Market: Regional Estimates & Trend Analysis

• 5.1. Regional Dashboard
• 5.2. Regional Female Infertility Diagnosis Market: Key Takeaways
• 5.3. North America
  • 5.3.1. North America Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.2. U.S.
    • 5.3.2.1. Key Country Dynamics
    • 5.3.2.2. Competitive Scenario
    • 5.3.2.3. Regulatory Framework
    • 5.3.2.4. Reimbursement scenario
    • 5.3.2.5. U.S. Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.3. Canada
    • 5.3.3.1. Key Country Dynamics
    • 5.3.3.2. Competitive Scenario
    • 5.3.3.3. Regulatory Framework
    • 5.3.3.4. Reimbursement scenario
    • 5.3.3.5. Canada Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.4. Mexico
    • 5.3.4.1. Key Country Dynamics
    • 5.3.4.2. Competitive Scenario
    • 5.3.4.3. Regulatory Framework
    • 5.3.4.4. Reimbursement scenario
    • 5.3.4.5. Mexico Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.5. Europe
  • 5.3.6. Europe Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.7. UK
    • 5.3.7.1. Key Country Dynamics
    • 5.3.7.2. Competitive Scenario
    • 5.3.7.3. Regulatory Framework
    • 5.3.7.4. Reimbursement scenario
    • 5.3.7.5. UK Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.8. Germany
    • 5.3.8.1. Key Country Dynamics
    • 5.3.8.2. Competitive Scenario
    • 5.3.8.3. Regulatory Framework
    • 5.3.8.4. Reimbursement scenario
    • 5.3.8.5. Germany Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.9. France
    • 5.3.9.1. Key Country Dynamics
    • 5.3.9.2. Competitive Scenario
    • 5.3.9.3. Regulatory Framework
    • 5.3.9.4. Reimbursement scenario
    • 5.3.9.5. France Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.10. Italy
    • 5.3.10.1. Key Country Dynamics
    • 5.3.10.2. Competitive Scenario
    • 5.3.10.3. Regulatory Framework
    • 5.3.10.4. Reimbursement scenario
    • 5.3.10.5. Italy Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.11. Spain
    • 5.3.11.1. Key Country Dynamics
    • 5.3.11.2. Competitive Scenario
    • 5.3.11.3. Regulatory Framework
    • 5.3.11.4. Reimbursement scenario
    • 5.3.11.5. Spain Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.12. Denmark
    • 5.3.12.1. Key Country Dynamics
    • 5.3.12.2. Competitive Scenario
    • 5.3.12.3. Regulatory Framework
    • 5.3.12.4. Reimbursement scenario
    • 5.3.12.5. Denmark Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.13. Sweden
    • 5.3.13.1. Key Country Dynamics
    • 5.3.13.2. Competitive Scenario
    • 5.3.13.3. Regulatory Framework
    • 5.3.13.4. Reimbursement scenario
    • 5.3.13.5. Sweden Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.14. Norway
    • 5.3.14.1. Key Country Dynamics
    • 5.3.14.2. Competitive Scenario
    • 5.3.14.3. Regulatory Framework
    • 5.3.14.4. Reimbursement scenario
    • 5.3.14.5. Norway Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Asia Pacific
  • 5.4.1. Asia Pacific Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Japan
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Competitive Scenario
    • 5.4.2.3. Regulatory Framework
    • 5.4.2.4. Reimbursement scenario
    • 5.4.2.5. Japan Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. China
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Competitive Scenario
    • 5.4.3.3. Regulatory Framework
    • 5.4.3.4. Reimbursement scenario
    • 5.4.3.5. China Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. India
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Competitive Scenario
    • 5.4.4.3. Regulatory Framework
    • 5.4.4.4. Reimbursement scenario
    • 5.4.4.5. India Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.5. South Korea
    • 5.4.5.1. Key Country Dynamics
    • 5.4.5.2. Competitive Scenario
    • 5.4.5.3. Regulatory Framework
    • 5.4.5.4. Reimbursement scenario
    • 5.4.5.5. South Korea Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.6. Australia
    • 5.4.6.1. Key Country Dynamics
    • 5.4.6.2. Competitive Scenario
    • 5.4.6.3. Regulatory Framework
    • 5.4.6.4. Reimbursement scenario
    • 5.4.6.5. Australia Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.7. Thailand
    • 5.4.7.1. Key Country Dynamics
    • 5.4.7.2. Competitive Scenario
    • 5.4.7.3. Regulatory Framework
    • 5.4.7.4. Reimbursement scenario
    • 5.4.7.5. Thailand Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Latin America
  • 5.5.1. Latin America Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. Brazil
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Competitive Scenario
    • 5.5.2.3. Regulatory Framework
    • 5.5.2.4. Reimbursement scenario
    • 5.5.2.5. Brazil Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Argentina
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Competitive Scenario
    • 5.5.3.3. Regulatory Framework
    • 5.5.3.4. Reimbursement scenario
    • 5.5.3.5. Argentina Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Middle East & Africa
  • 5.6.1. Middle East & Africa Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.2. South Africa
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Competitive Scenario
    • 5.6.2.3. Regulatory Framework
    • 5.6.2.4. Reimbursement scenario
    • 5.6.2.5. South Africa Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. Saudi Arabia
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Competitive Scenario
    • 5.6.3.3. Regulatory Framework
    • 5.6.3.4. Reimbursement scenario
    • 5.6.3.5. Saudi Arabia Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. UAE
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Competitive Scenario
    • 5.6.4.3. Regulatory Framework
    • 5.6.4.4. Reimbursement scenario
    • 5.6.4.5. UAE Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. Kuwait
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Competitive Scenario
    • 5.6.5.3. Regulatory Framework
    • 5.6.5.4. Reimbursement scenario
    • 5.6.5.5. Kuwait Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Market Participant Categorization
• 6.2. Company Market Position Analysis
• 6.3. Key Company Profiles
  • 6.3.1. PFCLA
    • 6.3.1.1. Company overview
    • 6.3.1.2. Financial performance
    • 6.3.1.3. Service benchmarking
    • 6.3.1.4. Strategic initiatives
  • 6.3.2. Mayo Foundation for Medical Education and Research (MFMER)
    • 6.3.2.1. Company overview
    • 6.3.2.2. Financial performance
    • 6.3.2.3. Service benchmarking
    • 6.3.2.4. Strategic initiatives
  • 6.3.3. Cleveland Clinic
    • 6.3.3.1. Company overview
    • 6.3.3.2. Financial performance
    • 6.3.3.3. Service benchmarking
    • 6.3.3.4. Strategic initiatives
  • 6.3.4. Apricity Fertility UK Limited
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Service benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. King's Fertility Limited
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Service benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. Dallas IVF
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Service benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Midwest Fertility Specialists
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Service benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. Europe IVF
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Service benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. Care Fertility
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Service benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. Aspire Fertility
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Service benchmarking
    • 6.3.10.4. Strategic initiatives

관련자료